[Market Feature] Rokit Healthcare Partners with China's Top Medical Device Firm... Up 11%

Rokit Healthcare is showing strong performance in early trading.

As of 9:07 a.m. on January 8, Rokit Healthcare was trading at 78,000 won, up 11.50% (7,300 won) from the previous day.

The news that the company has formed a partnership with WEGO Group, China's leading medical device company, to commercialize an artificial intelligence (AI) organ regeneration platform is seen as boosting investor sentiment.

With expectations rising that President Lee Jaemyung's state visit to China will pave the way for Korea-China cooperation in AI bio-healthcare, Rokit Healthcare is anticipated to leverage fast-track approval from Chinese regulatory authorities and target the 1.4 trillion won Chinese skin regeneration market. According to the company, immediate commercialization and revenue generation are expected to be possible in the second half of this year.

A representative from WEGO Group stated, "The number of diabetic foot ulcer (DFU), burn, and skin cancer patients in China targeted by both companies is close to 10 million," adding, "Even securing just a 10% market share in China would generate value of more than $1 billion (approximately 1.4 trillion won)."